The applause sign in frontotemporal lobar degeneration and related conditions.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 28 07 2018
accepted: 19 11 2018
revised: 09 11 2018
pubmed: 7 12 2018
medline: 29 5 2019
entrez: 4 12 2018
Statut: ppublish

Résumé

The applause sign, i.e., the inability to execute the same amount of claps as performed by the examiner, was originally reported as a sign specific for progressive supranuclear palsy (PSP). Recent research, however, has provided evidence for the occurrence of the applause sign in various conditions. The aim of this study was to determine the prevalence of the applause sign and correlate its presence with neuropsychological and MRI volumetry findings in frontotemporal lobar degeneration and related conditions. The applause sign was elicited with the three clap test (TCT), with a higher score indicating poorer performance. Data were recorded from 272 patients from the cohort of the German consortium for frontotemporal lobar degeneration (FTLDc): 111 with behavioral variant frontotemporal dementia (bvFTD), 98 with primary progressive aphasia (PPA), 30 with progressive supranuclear palsy Richardson's syndrome, 17 with corticobasal syndrome (CBS) and 16 with amyotrophic lateral sclerosis with frontotemporal dementia (ALS/FTD). For comparison, 29 healthy elderly control subjects (HC) were enrolled in the study. All subjects underwent detailed language and neuropsychological assessment. In a subset of 156 subjects, atlas-based volumetry was performed. The applause sign occurred in all patient groups (40% in PSP, 29.5% in CBS, 25% in ALS/FTD, 13.3% in PPA and 9.0% in bvFTD) but not in healthy controls. The prevalence was highest in PSP patients. It was significantly more common in PSP as compared to bvFTD, PPA and HC. The comparison between the other groups failed to show a significant difference regarding the occurrence of the applause sign. The applause sign was highly correlated to a number of neuropsychological findings, especially to measures of executive, visuospatial, and language function as well as measures of disease severity. TCT scores showed an inverse correlation with the volume of the ventral diencephalon and the pallidum. Furthermore the volume of the ventral diencephalon and pallidum were significantly smaller in patients displaying the applause sign. Our study confirms the occurrence of the applause sign in bvFTD, PSP and CBS and adds PPA and ALS/FTD to these conditions. Although still suggestive of PSP, clinically it must be interpreted with caution. From the correlation with various cognitive measures we suggest the applause sign to be indicative of disease severity. Furthermore we suggest that the applause sign represents dysfunction of the pallidum and the subthalamic nucleus, structures which are known to play important roles in response inhibition.

Identifiants

pubmed: 30506397
doi: 10.1007/s00415-018-9134-y
pii: 10.1007/s00415-018-9134-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

330-338

Subventions

Organisme : German Federal Ministry of Education and Research
ID : FTLDc 01GI1007A
Organisme : JPND network PreFrontAls
ID : 01ED1512
Organisme : EU
ID : FAIR-PARK II 633190
Organisme : German Research Foundation/DFG
ID : SFB1279
Organisme : Foundation of the state Baden-Württemberg
ID : D.3830
Organisme : Boehringer Ingelheim Ulm University BioCenter
ID : D.5009

Références

Eur J Neurosci. 2001 Apr;13(8):1609-16
pubmed: 11328354
Ann N Y Acad Sci. 2002 Apr;956:484-6
pubmed: 11960847
Acta Neuropathol. 2003 Jun;105(6):610-4
pubmed: 12669238
Mov Disord. 2003 May;18(5):467-86
pubmed: 12722160
Arch Neurol. 2004 May;61(5):697-700
pubmed: 15148146
Neurology. 2005 Jun 28;64(12):2132-3
pubmed: 15985587
J Neurosci. 2006 Mar 1;26(9):2424-33
pubmed: 16510720
Cereb Cortex. 2008 Jan;18(1):178-88
pubmed: 17517682
Neuroimage. 2007 Oct 15;38(1):95-113
pubmed: 17761438
J Neurol. 2007 Oct;254(10):1366-9
pubmed: 17934886
J Neurosci. 2007 Oct 31;27(44):11860-4
pubmed: 17978025
Neuroimage. 2008 Feb 1;39(3):1064-80
pubmed: 18037310
Magn Reson Imaging. 2008 Jun;26(5):594-601
pubmed: 18158224
Neuroimage. 2008 Jul 15;41(4):1352-63
pubmed: 18485743
Mov Disord. 2008 Dec 15;23(16):2426-8
pubmed: 18855927
Mov Disord. 2008 Dec 15;23(16):2307-11
pubmed: 18972544
Amyotroph Lateral Scler. 2009 Jun;10(3):131-46
pubmed: 19462523
Neuroimage. 2010 Feb 1;49(3):2216-24
pubmed: 19878722
J Neurol Neurosurg Psychiatry. 2011 Aug;82(8):830-3
pubmed: 21245475
J Neurol. 2011 Jun;258(6):1180-2
pubmed: 21267592
Neurology. 2011 Mar 15;76(11):1006-14
pubmed: 21325651
Hum Brain Mapp. 2012 Jul;33(7):1526-35
pubmed: 21618662
AJNR Am J Neuroradiol. 2011 Aug;32(7):1328-32
pubmed: 21680653
Nervenarzt. 2011 Aug;82(8):1002-5
pubmed: 21805118
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
Neuroimage. 2012 Feb 1;59(3):2860-70
pubmed: 21979383
Neuroimage. 2012 Mar;60(1):271-8
pubmed: 22209815
Exp Neurol. 2013 Jan;239:1-12
pubmed: 22975442
J Neurol. 2013 Jan;260(1):172-5
pubmed: 23010943
J Neurol. 2013 Apr;260(4):1099-103
pubmed: 23212756
Clin Neurol Neurosurg. 2013 Aug;115(8):1230-3
pubmed: 23253819
Neurology. 2013 Jan 29;80(5):496-503
pubmed: 23359374
J Clin Neurosci. 2013 Dec;20(12):1734-6
pubmed: 23972562
Neurology. 2013 Dec 10;81(24):2107-15
pubmed: 24212388
Trends Cogn Sci. 2014 Apr;18(4):177-85
pubmed: 24440116
J Neurol Neurosurg Psychiatry. 2014 Jul;85(7):823-4
pubmed: 24487382
Mov Disord. 2014 Apr;29(4):479-87
pubmed: 24488721
PLoS One. 2014 Mar 03;9(3):e90814
pubmed: 24595028
Alzheimers Dement. 2015 Jan;11(1):58-69
pubmed: 24795085
Clin Neurol Neurosurg. 2015 Oct;137:8-10
pubmed: 26117556
Magn Reson Imaging. 2016 May;34(4):455-61
pubmed: 26723849
Mov Disord. 2016 Oct;31(10):1506-1517
pubmed: 27452874
BMC Neurol. 2016 Aug 09;16:131
pubmed: 27506761
J Neurosci. 1995 Oct;15(10):6531-41
pubmed: 7472415
Adv Neurol. 1995;65:29-41
pubmed: 7872147

Auteurs

Sonja Schönecker (S)

Neurologische Klinik und Poliklinik, Ludwig Maximilians Universität München, Munich, Germany. sonja.schoenecker@med.uni-muenchen.de.

Franz Hell (F)

Neurologische Klinik und Poliklinik, Ludwig Maximilians Universität München, Munich, Germany.

Kai Bötzel (K)

Neurologische Klinik und Poliklinik, Ludwig Maximilians Universität München, Munich, Germany.

Elisabeth Wlasich (E)

Neurologische Klinik und Poliklinik, Ludwig Maximilians Universität München, Munich, Germany.

Nibal Ackl (N)

Neurologische Klinik und Poliklinik, Ludwig Maximilians Universität München, Munich, Germany.

Christine Süßmair (C)

Neurologische Klinik und Poliklinik, Ludwig Maximilians Universität München, Munich, Germany.

Markus Otto (M)

Department of Neurology, University of Ulm, Ulm, Germany.

Sarah Anderl-Straub (S)

Department of Neurology, University of Ulm, Ulm, Germany.

Albert Ludolph (A)

Department of Neurology, University of Ulm, Ulm, Germany.

Jan Kassubek (J)

Department of Neurology, University of Ulm, Ulm, Germany.

Hans-Jürgen Huppertz (HJ)

Swiss Epilepsy Clinic, Klinik Lengg, Zurich, Switzerland.

Janine Diehl-Schmid (J)

Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich, Germany.

Lina Riedl (L)

Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich, Germany.

Carola Roßmeier (C)

Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich, Germany.

Klaus Fassbender (K)

Department of Neurology, Saarland University, Homburg, Germany.

Epameinondas Lyros (E)

Department of Neurology, Saarland University, Homburg, Germany.

Johannes Kornhuber (J)

Department of Psychiatry and Psychotherapy, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.

Timo Jan Oberstein (TJ)

Department of Psychiatry and Psychotherapy, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.

Klaus Fliessbach (K)

Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Anja Schneider (A)

Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Matthias L Schroeter (ML)

Max Planck Institute of Human Cognitive and Brain Sciences (MPG), Leipzig, Germany.
Clinic for Cognitive Neurology, University Hospital Leipzig, Leipzig, Germany.

Johannes Prudlo (J)

Department of Neurology, Rostock University Medical Center, Rostock, Germany.
German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.

Martin Lauer (M)

Department of Psychiatry and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany.

Holger Jahn (H)

Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
AMEOS Klinikum Heiligenhafen, Heiligenhafen, Germany.

Johannes Levin (J)

Neurologische Klinik und Poliklinik, Ludwig Maximilians Universität München, Munich, Germany.
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.

Adrian Danek (A)

Neurologische Klinik und Poliklinik, Ludwig Maximilians Universität München, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH